
Hormones
Ipamorelin
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed at Novo Nordisk and described in 1998 as the first selective agent of its class.
- Container
- Glass vial, crimp seal, flip-top cap
- Storage
- -20 °C, desiccated
- Paperwork
- Lot certificate (HPLC + mass spec) shown before you pay
Lot certificates
You’ll see American Peptides on the lab’s copy. They’re our supplier.
- 5 mg, lot IPA5-0803: 99.78% purity (RP-HPLC), 5.17 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7600
- 10 mg, lot IPA10-0803: 99.78% purity (RP-HPLC), 10.15 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7624
Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.
What researchers study it for
- Selective growth hormone release
- Pituitary hormone selectivity in animal models
- Human pharmacokinetics and GH response
- Postoperative ileus (phase 2 trial)
How it is thought to work
Ipamorelin acts on the ghrelin receptor (GHS-R1a), stimulating growth hormone release from the pituitary. In swine it did not raise ACTH or cortisol, unlike GHRP-2 and GHRP-6. A human study in healthy volunteers observed a single, short-lived GH release episode.
Where the research stands
Phase 2 tested; not approved. A phase 2 placebo-controlled trial in bowel-resection patients (NCT00672074, 117 enrolled) found it well tolerated but showed no significant difference from placebo on recovery endpoints.
Sources
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH (1998). Ipamorelin, the first selective growth hormone secretagogue.. Eur J Endocrinol.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.. Pharm Res.
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.. Int J Colorectal Dis.
- Helsinn Therapeutics (U.S.), Inc (sponsor) (). A Phase II, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Ipamorelin Compared to Placebo for the Management of Post-Operative Ileus in Patients. ClinicalTrials.gov.
Read more
For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.
